Use of CRISPR/Cas9-mediated disruption of CNS cell type genes to profile transduction of AAV by neonatal intracerebroventricular delivery in miceTess Torregrosa(Biogen (United States)), Shih‐Ching Lo(Biogen (United States))Gene TherapyFebruary 22, 202110.1038/s41434-021-00223-3Cited by 20SaveCiteExport RISWatch citationsRelated PapersHighly efficient neuronal gene knockout in vivo by CRISPR-Cas9 via neonatal intracerebroventricular injection of AAV in mice|Gene Therapy|2021|45Caspase-3 Deficiency Results in Disrupted Synaptic Homeostasis and Impaired Attention Control|Journal of Neuroscience|2015|39